Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$5.63 USD

5.63
1,474,748

-0.25 (-4.25%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $5.63 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Sell Stocks for May 17th

by Zacks Equity Research

BIDU, EBS and FRO have been added to the Zacks Rank #5 (Strong Sell) List on May 17, 2023.

Zacks Equity Research

ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray

by Zacks Equity Research

ARS Pharmaceuticals (SPRY) gains as it gets favorable votes from the FDA advisory committee for epinephrine spray to treat severe allergic reactions.

Zacks Equity Research

Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.

Zacks Equity Research

Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -89.82% and 15.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More

by Kinjel Shah

Let us look at five biotech companies, NVAX, EBS, BLUE, EXEL and NKTR, which are gearing up for their earnings release.

Zacks Equity Research

Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

Is ALPS International Sector Dividend Dogs ETF (IDOG) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IDOG

Zacks Equity Research

Emergent Biosciences (EBS) Surges 28% in a Week: Here's Why

by Zacks Equity Research

Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.

Zacks Equity Research

Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose

by Zacks Equity Research

Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of this year.

Zacks Equity Research

Emergent Biosolutions (EBS) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Emergent Biosolutions (EBS) Down 28.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Emergent's (EBS) Q4 Earnings Miss, Sales Beat Estimates

by Zacks Equity Research

Emergent (EBS) reported mixed fourth-quarter 2022 results. While the company significantly misses the mark on earnings, it beat sales estimates.

Zacks Equity Research

Wall Street Analysts Believe Emergent Biosolutions (EBS) Could Rally 134.29%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 134.3% upside potential for Emergent Biosolutions (EBS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -196.88% and 7.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 87.04% and 0.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates

by Zacks Equity Research

Earnings results from Biogen (BIIB) and updates from EBS are the key highlights from the biotech sector during the past week.

Zacks Equity Research

Emergent Biosolutions (EBS) Moves 12.5% Higher: Will This Strength Last?

by Zacks Equity Research

Emergent Biosolutions (EBS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -27.94% and 65.46%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is ALPS International Sector Dividend Dogs ETF (IDOG) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IDOG

Zacks Equity Research

Emergent (EBS) to Start Restructuring Plan, Lays Off 5% Workforce

by Zacks Equity Research

Once this restructuring activity is completed, Emergent BioSolutions (EBS) expects to result in annualized savings of over $60 million. It also slightly raised its total revenue guidance for 2022.

Zacks Equity Research

Why Is Emergent Biosolutions (EBS) Down 3.7% Since Last Earnings Report?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.